title: Kasabach-Merritt syndrome with partial resection of tumor, reduction of tumor blood, and vincristine chemotherapy.
abstract: Kasabach-Merritt syndrome is a life-threatening and localized consumptive coagulopathy and characterized by profound thrombocytopenia and microangiopathic anemia. The huge tumor is the major cause of rapid platelet destruction, so we supposed that the reduction of tumor could reduce the platelet destruction and improve the clinical condition. In our cases, the vascular tumor occupied one of the extremities, head or face; however, removal of the whole tumor will result in the amputation of this extremity or the destruction of the face, and partial removal of the tumor and a U-shape suture to reduce tumor blood supply will be suitable. The wound could be repaired with skin graft or flaps. Vincristine chemotherapy after operation is necessary to prevent the enlargement of the remaining tumor.
authors.affiliation: Department of Plastic Surgery, Nanjing Children's Hospital, Nanjing Medical University, Nanjing, China. shenweimincn@hotmail.com
authors.forename: Weiming
authors.initials: W
authors.lastname: Shen
authors.forename: Jie
authors.initials: J
authors.lastname: Cui
authors.forename: Jianbin
authors.initials: J
authors.lastname: Chen
authors.forename: Jijun
authors.initials: J
authors.lastname: Zou
authors.forename: Yi
authors.initials: Y
authors.lastname: Ji
authors.forename: Haini
authors.initials: H
authors.lastname: Chen
mesh_terms: D003131:Combined Modality Therapy; D006390:Hemangioendothelioma / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007223:Infant; D017713:Platelet Transfusion; D013536:Suture Techniques; D013921:Thrombocytopenia / Q000188:drug therapy; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine